BNTX — BioNTech SE catalysts
Next verified catalyst
2026-07-23 — A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Childr · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07-23 in 1mo
ESTIMATED |
READOUT
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Heal
Phase 3 · SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2 |
BNTX BioNTech SE | Bivalent BNT162b2 (original/Omicron BA.4 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07-31 in 1mo
ESTIMATED |
READOUT
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in C
Phase 3 · COVID-19, SARS-COV-2 Infection |
BNTX BioNTech SE | BNT162b2 (2025/2026 formulation) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07-31 in 1mo
ESTIMATED |
READOUT
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years
Phase 3 · COVID-19, SARS-COV-2 Infection |
BNTX BioNTech SE | BNT162b2 Vaccine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Wa
Phase 2 · Colorectal Cancer Stage II, Colorectal Cancer Stage III |
BNTX BioNTech SE | RO7198457 intravenous (IV), Observationa |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|